The transient activation of the RAF-MEK1/2-ERK1/2 signaling axis in the early infection phase of SARS-CoV-2 was previous described and the MEK1/2 inhibitor ATR-002 displayed strong anti-SARS-CoV-2 activity (Schreiber et al, 2022). This evidence concerns the gene MAPK3 and infection.